CN102573459A - 粘度降低的浓缩多肽制剂 - Google Patents

粘度降低的浓缩多肽制剂 Download PDF

Info

Publication number
CN102573459A
CN102573459A CN2010800445005A CN201080044500A CN102573459A CN 102573459 A CN102573459 A CN 102573459A CN 2010800445005 A CN2010800445005 A CN 2010800445005A CN 201080044500 A CN201080044500 A CN 201080044500A CN 102573459 A CN102573459 A CN 102573459A
Authority
CN
China
Prior art keywords
preparation
polypeptide
antibody
dmso
dma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800445005A
Other languages
English (en)
Chinese (zh)
Inventor
T·卡梅尔泽尔
S·马丁-莫
J·Y·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN102573459A publication Critical patent/CN102573459A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2010800445005A 2009-08-04 2010-08-03 粘度降低的浓缩多肽制剂 Pending CN102573459A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23114009P 2009-08-04 2009-08-04
US61/231,140 2009-08-04
PCT/US2010/044258 WO2011017330A1 (en) 2009-08-04 2010-08-03 Concentrated polypeptide formulations with reduced viscosity

Publications (1)

Publication Number Publication Date
CN102573459A true CN102573459A (zh) 2012-07-11

Family

ID=43544629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800445005A Pending CN102573459A (zh) 2009-08-04 2010-08-03 粘度降低的浓缩多肽制剂

Country Status (15)

Country Link
US (1) US20130236448A1 (enExample)
EP (1) EP2461677A4 (enExample)
JP (1) JP2013501058A (enExample)
KR (1) KR20120047995A (enExample)
CN (1) CN102573459A (enExample)
AU (1) AU2010279569A1 (enExample)
BR (1) BR112012002596A2 (enExample)
CA (1) CA2769221A1 (enExample)
IL (1) IL217887A0 (enExample)
MX (1) MX2012001560A (enExample)
NZ (1) NZ598518A (enExample)
RU (1) RU2012108108A (enExample)
SG (1) SG178226A1 (enExample)
WO (1) WO2011017330A1 (enExample)
ZA (1) ZA201200760B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105705139A (zh) * 2013-09-11 2016-06-22 阿尔西亚治疗有限公司 包含水溶性有机染料的液体蛋白质制剂
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
DK2672986T3 (da) 2011-02-09 2020-06-08 Glaxosmithkline Llc Frysetørrede formuleringer
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
CN105793850B (zh) * 2013-11-29 2020-04-24 豪夫迈·罗氏有限公司 抗体选择装置和方法
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116700A1 (en) * 2000-10-12 2007-05-24 Genentech, Inc. Reduced-Viscosity Concentrated Protein Formulations
CN101014319A (zh) * 2004-06-04 2007-08-08 卡穆鲁斯公司 液体贮库制剂
US20080085263A1 (en) * 2004-06-04 2008-04-10 Krister Thuresson Liquid Depot Formulations
CN101193652A (zh) * 2005-04-08 2008-06-04 安米林药品公司 包含肠降血糖素肽和非质子极性溶剂的药物制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY25089A1 (es) * 1997-07-10 2000-08-21 Hoechst Roussel Vet Gmbh Vacunas no acuosas
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1968961A (zh) * 2004-06-14 2007-05-23 Usv有限公司 制备肽的方法
WO2007076062A2 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070116700A1 (en) * 2000-10-12 2007-05-24 Genentech, Inc. Reduced-Viscosity Concentrated Protein Formulations
CN101014319A (zh) * 2004-06-04 2007-08-08 卡穆鲁斯公司 液体贮库制剂
US20080085263A1 (en) * 2004-06-04 2008-04-10 Krister Thuresson Liquid Depot Formulations
CN101193652A (zh) * 2005-04-08 2008-06-04 安米林药品公司 包含肠降血糖素肽和非质子极性溶剂的药物制剂

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111202711A (zh) * 2013-09-11 2020-05-29 伊戈尔生物药品股份有限公司 包含有机磷酸酯的液体蛋白质制剂
US11819550B2 (en) 2013-09-11 2023-11-21 Eagle Biologics, Inc. Liquid protein formulations containing cyclic adenosine monophosphate (cAMP) or adenosine triphosphate (ATP)
US10179172B2 (en) 2013-09-11 2019-01-15 Eagle Biologics, Inc. Liquid pharmaceutical formulations for injection comprising yellow 5 or orange G and uses thereof
CN105705139B (zh) * 2013-09-11 2019-07-26 伊戈尔生物药品股份有限公司 包含水溶性有机染料的液体蛋白质制剂
CN105722501B (zh) * 2013-09-11 2019-07-26 伊戈尔生物药品股份有限公司 包含粘度降低剂的液体蛋白质制剂
US10646571B2 (en) 2013-09-11 2020-05-12 Eagle Biologics, Inc. Liquid protein formulations containing cimetidine
US10821184B2 (en) 2013-09-11 2020-11-03 Eagle Biologics, Inc. Liquid protein formulations containing thiamine pyrophosphate (TPP)
CN105705139A (zh) * 2013-09-11 2016-06-22 阿尔西亚治疗有限公司 包含水溶性有机染料的液体蛋白质制剂
CN105722501A (zh) * 2013-09-11 2016-06-29 阿尔西亚治疗有限公司 包含粘度降低剂的液体蛋白质制剂
US10849977B2 (en) 2013-09-11 2020-12-01 Eagle Biologics, Inc. Liquid Protein Formulations Containing Thiamine
CN111202711B (zh) * 2013-09-11 2022-06-21 伊戈尔生物药品股份有限公司 包含有机磷酸酯的液体蛋白质制剂
US11986526B2 (en) 2013-09-11 2024-05-21 Eagle Biologics, Inc. Liquid protein formulations containing 4-ethyl-4-methylmorpholinium methylcarbonate (EMMC)
US10821183B2 (en) 2013-09-11 2020-11-03 Eagle Biologics, Inc. Liquid protein formulations containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM)
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents

Also Published As

Publication number Publication date
JP2013501058A (ja) 2013-01-10
BR112012002596A2 (pt) 2015-09-15
IL217887A0 (en) 2012-03-29
ZA201200760B (en) 2013-05-29
US20130236448A1 (en) 2013-09-12
WO2011017330A8 (en) 2011-04-21
AU2010279569A1 (en) 2012-03-01
MX2012001560A (es) 2012-06-01
RU2012108108A (ru) 2013-09-10
CA2769221A1 (en) 2011-02-10
KR20120047995A (ko) 2012-05-14
EP2461677A4 (en) 2014-01-08
SG178226A1 (en) 2012-03-29
NZ598518A (en) 2014-12-24
EP2461677A1 (en) 2012-06-13
WO2011017330A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
US12152054B2 (en) Methods of purifying polypeptides
JP6979442B2 (ja) オーバーロード／溶出クロマトグラフィー
CN102573459A (zh) 粘度降低的浓缩多肽制剂
KR20220017436A (ko) 과부하 크로마토그래피 컬럼의 재생 방법
HK1170633A (en) Concentrated polypeptide formulations with reduced viscosity
JP2025510828A (ja) ポリペプチドを安定化するためのヒドロキシプロピルメチルセルロース誘導体
HK1240254B (zh) 超载和洗脱层析
HK1181326A (en) Methods of purifying polypeptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1170633

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120711

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1170633

Country of ref document: HK